Skip to main navigation Skip to search Skip to main content

Healthy longevity-associated protein improves cardiac function in murine models of cardiomyopathy with preserved ejection fraction

  • Valeria V Alvino
  • , Sadie C Slater
  • , Yan Qiu
  • , Monica Cattaneo
  • , Khaled Abdelsattar A K Mohammed
  • , Seamus Gate
  • , Vealmurugan Sekar
  • , Annibale A Puca*
  • , Paolo R Madeddu*
  • *Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

4 Citations (Scopus)

Abstract

Aims
Aging is influenced by genetic determinants and comorbidities, among which diabetes increases the risk for heart failure with preserved ejection fraction. There is no therapy to prevent heart dysfunction in aging and diabetic individuals. In previous studies, a single administration of the longevity-associated variant (LAV) of the human BPIFB4 gene halted heart decline in older and type 2 diabetic mice. Here, we asked whether orally administered LAV-BPIFB4 protein replicates these benefits.

Materials and Methods
In two controlled, randomized studies, 18-month-old male C57BL/6 J mice and 9-week-old C57BLKS/J-Leprdb/Leprdb/Dock7 + [db/db] mice of both sexes underwent baseline echocardiography. They then received a recombinant purified LAV-BPIFB4 protein (3 µg/animal, every three days) or vehicle by gavage. After 30 days, the animals underwent echocardiography, and the hearts were collected post-termination for histology.

Results
All the animals completed the study except one female diabetic mouse, which was culled prematurely because tooth malocclusion caused eating problems. There was no effect of the LAV-BPIFB4 protein on body weight in the two studies or glycosuria in the diabetic study. In aging mice, LAV-BPIFB4 increased myocardial Bpifb4 expression, improving heart contractility and capillarity while reducing perivascular fibrosis and senesce. In male diabetic mice, LAV-BPIFB4 therapy improved systolic function, microvascular density, and senescence, whereas the benefit was limited to systolic function in females.

Conclusions
This study shows the feasibility and efficacy of a variant protein associated with human longevity in contrasting pivotal risk factors for heart failure in animal models. The diabetic study revealed that sex influences the treatment efficacy.
Original languageEnglish
Article number397
Number of pages12
JournalCardiovascular Diabetology
Volume23
Issue number1
DOIs
Publication statusPublished - 5 Nov 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

Fingerprint

Dive into the research topics of 'Healthy longevity-associated protein improves cardiac function in murine models of cardiomyopathy with preserved ejection fraction'. Together they form a unique fingerprint.

Cite this